Details

Autor(en) / Beteiligte

• Pinto, Yishay
• Frishman, Sigal
• Turjeman, Sondra
• Eshel, Adi
• Nuriel-Ohayon, Meital
• Shrossel, Oshrit
• Ziv, Oren
• Walters, William
• Parsonnet, Julie
• Ley, Catherine
• Johnson, Elizabeth L
• Kumar, Krithika
• Schweitzer, Ron
• Khatib, Soliman
• Magzal, Faiga
• Muller, Efrat
• Tamir, Snait
• Tenenbaum-Gavish, Kinneret
• Rautava, Samuli
• Salminen, Seppo
• Isolauri, Erika
• Yariv, Or
• Peled, Yoav
• Poran, Eran
• Pardo, Joseph
• Chen, Rony
• Hod, Moshe
• Borenstein, Elhanan
• Ley, Ruth E
• Schwartz, Betty
• Louzoun, Yoram
• Hadar, Eran
• Koren, Omry

Titel

Gestational diabetes is driven by microbiota-induced inflammation months before diagnosis

Ist Teil von

• Gut, 2023-05, Vol.72 (5), p.918

Ort / Verlag

England

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Gestational diabetes mellitus (GDM) is a condition in which women without diabetes are diagnosed with glucose intolerance during pregnancy, typically in the second or third trimester. Early diagnosis, along with a better understanding of its pathophysiology during the first trimester of pregnancy, may be effective in reducing incidence and associated short-term and long-term morbidities. We comprehensively profiled the gut microbiome, metabolome, inflammatory cytokines, nutrition and clinical records of 394 women during the first trimester of pregnancy, before GDM diagnosis. We then built a model that can predict GDM onset weeks before it is typically diagnosed. Further, we demonstrated the role of the microbiome in disease using faecal microbiota transplant (FMT) of first trimester samples from pregnant women across three unique cohorts. We found elevated levels of proinflammatory cytokines in women who later developed GDM, decreased faecal short-chain fatty acids and altered microbiome. We next confirmed that differences in GDM-associated microbial composition during the first trimester drove inflammation and insulin resistance more than 10 weeks prior to GDM diagnosis using FMT experiments. Following these observations, we used a machine learning approach to predict GDM based on first trimester clinical, microbial and inflammatory markers with high accuracy. GDM onset can be identified in the first trimester of pregnancy, earlier than currently accepted. Furthermore, the gut microbiome appears to play a role in inflammation-induced GDM pathogenesis, with interleukin-6 as a potential contributor to pathogenesis. Potential GDM markers, including microbiota, can serve as targets for early diagnostics and therapeutic intervention leading to prevention.